PHA 543613
CAS No. 478149-53-0
PHA 543613( —— )
Catalog No. M33906 CAS No. 478149-53-0
PHA 543613 is a specific agonist of α7 nAChR (Ki = 8.8 nM) and can be used in studies about the cognitive deficits of Alzheimer's disease and schizophrenia.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 70 | Get Quote |
|
| 5MG | 104 | Get Quote |
|
| 10MG | 169 | Get Quote |
|
| 25MG | 365 | Get Quote |
|
| 50MG | 624 | Get Quote |
|
| 100MG | 896 | Get Quote |
|
| 500MG | 1944 | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NamePHA 543613
-
NoteResearch use only, not for human use.
-
Brief DescriptionPHA 543613 is a specific agonist of α7 nAChR (Ki = 8.8 nM) and can be used in studies about the cognitive deficits of Alzheimer's disease and schizophrenia.
-
DescriptionPHA-543613 is a potent, orally active, brain-penetrant and selective α7 nAChR agonist with a Ki of 8.8 nM. PHA-543613 displays selectivity for α7-nAChR over α3β4, α1β1γδ, α4β2 and 5-HT3 receptors. PHA-543613 can be used for the cognitive deficits of Alzheimer's disease and schizophrenia research.
-
In Vitro——
-
In VivoAnimal Model:Male CD-1 mice with (intracerebral hemorrhage) ICH-induction or sham surgeryDosage:4 and 12 mg/kg Administration:Intraperitoneal injection; 4 and 12 mg/kg; 1 hour after surgery Result:Increased p-Akt and decreased p-GSK-3 and CC3 expressions in the ipsilateral hemisphere and reduced the neuronal cell death in the perihematomal area. Attenuated behavioral deficits and brain edema at 72 hours after ICH.
-
Synonyms——
-
PathwayCell Cycle/DNA Damage
-
TargetAChR
-
RecptorAChR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number478149-53-0
-
Formula Weight271.31
-
Molecular FormulaC15H17N3O2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 250 mg/mL (921.46 mM; Ultrasonic )H2O : 100 mg/mL (368.58 mM; Ultrasonic)
-
SMILESO=C(N[C@H]1CN2CCC1CC2)c1cc2ccoc2cn1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Donn G Wishka, et al. Discovery of N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide, an agonist of the alpha7 nicotinic acetylcholine receptor, for the potential treatment of cognitive deficits in schizophrenia: synthesis and structure--activity relationship. J Med Chem. 2006 Jul 13;49(14):4425-36. ?
molnova catalog
related products
-
SSR 180
SSR 180 is a potent and subtype-selective α7 agonist with applications in the study of Alzheimer;s disease and schizophrenia.
-
Pozanicline dihydroc...
Pozanicline dihydrochloride is an orally bioavailable agonist of nicotinic acetylcholine receptor (nAChR) (Ki = 16.7 nM).
-
ASM-024
ASM-024, a potent nicotinic receptor agonist, is a small molecule synthetic piperazine compound that promotes different targets and signaling pathways of β2-adrenergic receptors mediating smooth muscle relaxation.
Cart
sales@molnova.com